CLINICAL_TRIALS
trial_result
· 2022-03-17
Clinical Trial Update: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) [Phase 3]
Summary
Phase 3 trial update for AR101 (peanut oral immunotherapy) in desensitization for children and adults with peanut allergy.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Aimmune Therapeutics, Inc. | Conditions: Peanut Allergy | Phase 3 | Status: COMPLETED | Results posted: 2022-03-17